GSK climbs as structural overhaul revealed
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has announced new plans to get itself back on track after disappointing drug sales and a mounting number of corruption accusations across the globe. Cost reduction strategies in response to the ongoing poor performance of its respiratory portfolio helped deliver third quarter EPS of 27.9p, up 5%. GSK intends to build on this by exploring an IPO of part of ViiV Healthcare, its majority-owned joint venture HIV business, and a further £1bn savings program.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.